Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02. Results of Operations and Financial Condition

On February23, 2017, Achillion Pharmaceuticals, Inc. (the
Company) announced its financial results for the fiscal year
ended December31, 2016. The full text of the press release issued
in connection with the announcement is furnished as Exhibit 99.1
to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:

99.1 Press Release dated February 23, 2017


About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Recent Trading Information

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed its last trading session up +0.04 at 4.24 with 1,131,501 shares trading hands.

An ad to help with our costs